Xeris Biopharma reported third quarter 2026 financial results that significantly exceeded consensus expectations, driven by a 93% year-over-year increase in Recorlev revenue. The company achieved a net income of $11.3 million and raised its full-year 2026 total revenue guidance to a range of $395 million to $405 million.
Key Highlights
- Recorlev net revenue surged to $71.5 million from $37.0 million in the prior-year period, fueled by record patient referrals and new starts following a commercial team expansion.
- Total revenue grew 44% year-over-year to $107.2 million, while gross margin improved to 88% due to a more favorable product mix.
- Management significantly raised its 2030 total revenue outlook to more than $1 billion, up from the previous target of approximately $750 million.